Publish, Ahead, o, 60 to 99

6 to 58

Preserved : 1990: 3(5), 1991: 4(1, 9), 1992: 5(3)

Preserved : 1994: 7(12)

Preserved : 1999: 21(1-5), 1999: 22(1-5), 2000: 23(1-5), 2000: 24(1-5), 2000: 25(1, S 1, 2, S 2, 3-5), 2001: 26(1, S 1, 2-5), 2001: 27(1-5), 2001: 28(1-5), 2002: 29(1, S 1, 2-5), 2002: 30(1, S 1, 2-5), 2002: 31(1, S 1, 2, S 2, 3, S 3, 4-5), 2003: 32(1, S 1, 2-5), 2003: 33(1-5), 2004: 35(1-5), 2004: 36(1-5), 2004: 37(1, S 1, 2, S 2, 3, S 3, 4, S 4, 5), 2005: 38(1, S 1, 2-5), 2005: 39(1, S 1, 2-5), 2005: 40(1-5), 2006: 41(1-5), 2006: 42(1, S 1 3, 2-5), 2006: 43(1, S 1, 2-5), 2007: 44(1-5), 2007: 45(1, S 1, Protease Inhibitors: The New Alternative?, 2-5), 2007: 46(1-5), 2008: 47(1-5), 2008: 48(1-5), 2008: 49(1, S 1, Project Eban: A Giant Step Forward, 2, S 2, HIV and Cardiometabolic Abnormalities: New Perspectives and Treatment Update, 3-5), 2009: 50(1-5), 2009: 51(1, S 1, HIV Infection in the Americas: Improving Strategic Information to Improve Response, 2, S 2, 11th Anniversary Annual International Meeting of the Institute of Human Virology, 3-5), 2009: 52(1-2, S 2, Progress Towards Global HIV Targets: Challenges in Monitoring National Indicators, 3-5), 2010: 53(1, S 1, China Meets New AIDS Challenges, 2-5), 2010: 54(1-5), 2010: 55(1-5), 2011: 56(1-2, s2, 12th Annual International Meeting of the Institute of Human Virology, 3-5), 2011: 57(1-5), 2011: 58(1-5), 2012: 59(1, s1, 13th Annual International Meeting of the Institute of Human Virology, 2-5), 2012: 60(1-5), 2012: 61(1-5), 2013: 62(1, s1, 14th Annual International Meeting of the Institute of Human Virology, 2-5), 2013: 63(1-5), 2013: 64(1-5), 2014: 65(1-2, s2, 15th Annual International Meeting of the Institute of Human Virology, 3-5), 2014: 66(1-5), 2014: 67(1-3, s3, 16th Annual International Meeting of the Institute of Human Virology, 4-5), 2015: 68(1-5), 2015: 69(1-5), 2015: 70(1-5), 2016: 71(1, s1, 17th Annual International Meeting of the Institute of Human Virology, 2-5), 2016: 72(1-5), 2016: 73(1-5), 2017: 74(1-5), 2017: 75(1-5), 2017: 76(1-5), 2018: 77(1-5), 2018: 78(1-5), 2018: 79(1-5), 2019: 80(1-5), 2019: 81(1-5), 2019: 82(1-5), 2020: 83(1-5), 2020: 84(1-5), 2020: 85(1-5), 2021: 86(1-5), 2021: 87(1-5), 2021: 88(1-5), 2022: 89(1, S1, 2-5), 2022: 90(1, S 1, 2-5), 2022: 91(1, S 1, 2-5), 2023: 92(1-5), 2023: 93(1-5), 2023: 94(1-2, 2, S, 3-5), 2024: 95(1, 1, S, 2-5), 2024: 96(1-5), 2024: 97(1-5), 2025: 98(1-5, 5, S), 2025: 99(1)